Sign in Subscribe
T cells

Caribou Biosciences Announces Promising Clinical Data for CB-011 in Relapsed or Refractory Multiple Myeloma

Strategic Insights

— 2 min read

Caribou Biosciences, a clinical-stage CRISPR genome-editing biopharmaceutical company, has announced encouraging clinical data from its phase 1 trial evaluating CB-011, an off-the-shelf anti-BCMA CAR-T cell therapy, in patients with relapsed or refractory multiple myeloma. The results highlight the potential of CB-011 as a best-in-class allogeneic CAR-T cell therapy for this patient population.

The data, from the CaMMouflage phase 1 clinical trial, demonstrated that CB-011 achieved deep, durable responses in 92% of patients, with 75% achieving complete response or greater and 91% achieving minimal residual disease (MRD) negativity. The therapy also showed a manageable safety profile, with no cases of graft-versus-host disease, immune effector cell-associated enterocolitis, parkinsonism, or cranial nerve palsies.

"We are very encouraged by the compelling results from the CaMMouflage phase 1 trial, which demonstrate that CB-011 is delivering deep, durable responses in high-risk, heavily pretreated multiple myeloma patients with a manageable safety profile," said Rachel Haurwitz, PhD, president and CEO of Caribou Biosciences.

Key Takeaways:

  • CB-011, an off-the-shelf anti-BCMA CAR-T cell therapy, achieved 92% overall response rate in patients with relapsed or refractory multiple myeloma.
  • The therapy demonstrated a 75% complete response or greater rate and 91% MRD negativity rate in the 12-patient cohort.
  • CB-011 showed a manageable safety profile, with no cases of graft-versus-host disease, immune effector cell-associated enterocolitis, parkinsonism, or cranial nerve palsies.
  • The recommended dose expansion (RDE) for CB-011 is 450x10^6 CAR-T cells.
  • Dose expansion to initiate by year-end, with data expected in 2026.
  • Prophylactic measures for cytopenias and infections, and early intervention for IEC-HS, have been successfully implemented in the protocol.
  • CB-011 has the potential to be a best-in-class allogeneic CAR-T cell therapy, expanding access and bringing meaningful benefit to patients with relapsed or refractory multiple myeloma.

Statistics:

  • 92% overall response rate (ORR) in the 12-patient cohort.
  • 75% complete response or greater (CR) rate.
  • 91% minimal residual disease (MRD) negativity rate.
  • No cases of graft-versus-host disease, immune effector cell-associated enterocolitis, parkinsonism, or cranial nerve palsies.
  • 80% neutropenia, 60% anemia, 49% thrombocytopenia, and 49% infections in patients treated with CB-011.
  • 450x10^6 CAR-T cells is the recommended dose expansion (RDE) for CB-011.

Sources:

  • Caribou Biosciences, Inc. press release, "Caribou Biosciences Announces Promising Clinical Data for CB-011 in Relapsed or Refractory Multiple Myeloma" (November 3, 2025).
  • Caribou Biosciences, Inc. corporate website, "CaMMouflage phase 1 clinical trial" ().
  • Caribou Biosciences, Inc. corporate website, "Caribou Biosciences, Inc. contact: Peggy Vorwald, PhD COMTEX_469991372/2010/2025-11-03T07:00:04".

Read more